<DOC>
	<DOCNO>NCT02117349</DOCNO>
	<brief_summary>The purpose study show Raplixa plus gelatin sponge well gelatin sponge alone stop mild moderate bleeding child surgery</brief_summary>
	<brief_title>Safety Efficacy Study Raplixa™ ( Fibrin Sealant Human ) Treat Surgical Bleeding Children</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<criteria>The study enroll subject undergo one follow surgical procedure : Vascular Surgery Hepatic surgery Soft tissue surgery Renal surgery Spinal surgery Inclusion Criteria ( presurgery ) : 1 . Age ≥36 week gestational age birth ( infant ) &lt; 18 year age time treatment 2 . Subject 's legal representative ( parent guardian ) sign institutional review board ( IRB ) approve informed consent document 3 . If subject ≥ 7 year old , appropriate age define local regulation , subject may require sign IRBapproved assent document 4 . Subject schedule undergo one surgical procedure describe 5 . If female childbearing potential , subject negative pregnancy test day surgery ( baseline ) 6 . If subject sexually active male sexually active female childbearing potential , subject agrees use medically accept form contraception time consent completion followup study visit . Inclusion Criteria ( surgery ) : 7 . Presence mild moderate bleeding/oozing 8 . Target Bleeding Sites surface area ≤100 cm2 9 . Has receive whole blood , fresh frozen plasma ( FFP ) , cryoprecipitate , platelet within 24 hour prior study drug . Packed red blood cell ( PRBC ) transfusion allow 10 . No complication surgery bleeding , opinion Investigator , may interfere assessment efficacy safety 1 . Gestational age &lt; 36 week birth ( infant less 6 month age ) 2 . Any clinicallysignificant congenital coagulation disorder ( e.g. , hemophilia A B ) may interfere assessment efficacy pose safety risk subject accord Investigator 3 . Baseline abnormalities international normalized ratio ( INR ) &gt; 2.5 activate partial thromboplastin time ( aPTT ) &gt; 100 second screen explain current drug treatment ( e.g. , warfarin , heparin ) chronic disease state necessitating surgery ( e.g. , end stage liver disease ) . 4 . Aspartate Aminotransferase ( ASAT/AST ) Alanine aminotransferase ( ALAT/ALT ) &gt; 3 x upper limit normal range screening , except subject undergo liver resection surgery diagnosis liver disease upper limit analytes due nature disease 5 . Subject unwilling receive blood product product derive human blood 6 . Platelets &lt; 100 x10ᴧ9 PLT/L screening unless due chronic disease state , e.g. , liver disease/failure , necessitate surgery 7 . Subject known antibody hypersensitivity Raplixa 's component , thrombin preparation coagulation factor 8 . Known allergy porcine gelatin 9 . Medical , social , psychosocial factor , opinion Investigator , could impact subject safety compliance study procedures 10 . Subject ; 1 ) currently participate another clinical study 2 ) participate another clinical study within 30 day screen 3 ) plan participate clinical study prior completion 30day followup period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>surgical hemostasis</keyword>
	<keyword>bleeding</keyword>
	<keyword>fibrin sealant</keyword>
	<keyword>fibrinogen</keyword>
	<keyword>thrombin</keyword>
	<keyword>spray dry</keyword>
</DOC>